Clinical trial
Phase I Study to Evaluate the Safety and Efficacy of MF101 as Well as the…
NCT00453297 · Bionovo, Industry · Terminated
Key facts
| NCT number | NCT00453297 |
|---|---|
| Title | Phase I Study to Evaluate the Safety and Efficacy of MF101 as Well as the Pharmacokinetics of Its Key Active Components |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Oral, Dose Escalation Phase 1 Study to Evaluate the Safety and Tolerance of MF 101 as Well as the Pharmacokinetics of Its Key Active Components in Healthy Post-Menopausal Women. |
| Lead sponsor | Bionovo, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | MF101 |
| Enrollment | 32 |
| Start date | Oct 1, 2006 |
| Completion | Apr 1, 2007 |
| First posted | Mar 28, 2007 |
| Last update posted | Aug 29, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: